A Trial for Prevention of Loss of the Effect of Biological Drugs in Patients With Inflammatory Bowel Disease

• ClinicalTrials.gov Identifier: NCT03843697
• Recruitment Status: Unknown
• First Posted: February 18, 2019
• Last Update Posted: February 18, 2019
• Sponsor: Tahel Ilan Ber
• Information provided by (Responsible Party): Tahel Ilan Ber, Oberon Sciences LTD

Study Description

Brief Summary:

Trial for IBD patients non-responsive to biological drugs, using medical app reminding patients to take their physician-prescribed medications

Condition or disease	Intervention/treatment	Phase
Inflammatory Bowel Diseases	Device: An App for reminding patients to take their medication	Not Applicable

Detailed Description:

Patients with IBD who developed loss of response to anti-TNF based medications will receive a cell phone based app that will remind them to take the drug with an approved dosing range.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 20 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Intervention Model Description: The study will assess the effect of adding an app which reminds to take an approved therapy in patients who are already on the drug without a change of the physician's predetermined regimen
• Masking: None (Open Label)
• Primary Purpose: Device Feasibility
• Official Title: A Controlled Trial for the Prevention of Loss of the Effect of Biological Drugs in Patients With Inflammatory Bowel Disease
• Estimated Study Start Date: March 1, 2019
• Estimated Primary Completion Date: January 1, 2020
• Estimated Study Completion Date: January 1, 2020

Arms and Interventions

Arm

Intervention/treatment

Experimental: Patients with IBD who develop resistance to anti TNF; Patients with inflammatory bowel disease who developed partial or complete resistance to anti TNF based drugs

Device: An App for reminding patients to take their medication; Open-label, single-center study, up to 20 adults (>18) male and female with inflammatory bowel disease (chorn's disease, ulcerative colitis), unresponsive to biological drugs, will participate in a 4-week observation period during which no change in drugs is permitted. The patients will then begin 10-week treatment by taking their medications according to a semi-random schedule that is pre-set for them by the physician using the same drugs the patient is taking and only changing the dose and times of taking them each day while keeping the drugs within their therapeutic window.; Other Name: Oberon APP

Outcome Measures

Primary Outcome Measures :

1. Proportion of subjects with reduction chron's disease activity index score more than 100 points during the study; [ Time Frame: 10 weeks ]
   Proportion of subjects with reduction chron's disease activity index score more than 100 points during the study;

Secondary Outcome Measures :

1. Proportion of subjects achieving clinical remission or response without steroid rescue therapy during the study; [ Time Frame: 10 weeks ]
   The secondary efficacy outcome was the proportion of subjects with clinical response at week 10

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 80 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Diagnosis of CD or UC according to validated criteria, with a Crohn's Disease Activity Score (CDAI) of 200-450 at inclusion.
2. Patients on a stable dose within the last 6 weeks of any type of anti TNF agent or any other biological agent
3. 5-ASA (mesalamine), and immunomodulatory, or immunosuppressive agent, and symptomatic relief (anti-diarrheals) for patients are allowed in a stable dose (6 weeks).
4. Non-smoking (by declaration) for a period of at least 6 months.
5. Females of childbearing potential must be non-pregnant (as determined by a serum pregnancy test at screening and again, prior to each dosing session) and agree to use adequate contraceptive means throughout the study.
6. No known history of significant neurological, renal, cardiovascular, respiratory (asthma), endocrinological, gastrointestinal, primary hematopoietic disease, neoplasm, or any other clinically significant medical disorder other than Crohn's disease and its complications, which in the investigator's judgment contraindicate administration of the study medications.
7. No history of drug or alcohol abuse.
8. Screening tests must meet the following criteria: HGB ≥8.5 g/dL, platelets ≥ 100,000/ mm³, WBC: 3500-12,000/mm³, serum albumin above 2.5 g/dL, amylase, lipase and total bilirubin within normal limits. ALT, AST, alkaline phosphatase up to 1.5 times normal limits.
9. No clinically significant abnormalities in screening physical exam.
10. Negative HIV, Hepatitis B and Hepatitis C serology tests within 2 years.
11. Patients must be able to adhere to the visit schedule and protocol requirements and be available to complete the study.
12. Patients must satisfy a medical examiner about their fitness to participate in the study.
13. Patients must provide written informed consent to participate in the study.

Exclusion Criteria:

1. Patients with evidence of other serious infectious, autoimmune, hepatic, nephritic or systemic disease or compromised organ function.
2. Patients with a present colostomy, ileostomy or subtotal colectomy with ileorectal anastomosis.
3. Symptomatic stenosis or ileal strictures, x-ray evidence of fibrosed bowel.
4. Patients presenting with, or with a history of persistent intestinal obstruction, bowel perforation, uncontrolled GI bleed or abdominal abscess or infection, toxic megacolon.
5. Patients with fistulating CD.
6. Short bowel syndrome.
7. Patients with a history of GI tract malignancy or IBD-associated malignant changes in the intestines.
8. Patients with any clinically significant abnormality upon physical examination or in the clinical laboratory test values.
9. A change in the dose of the immunomodulatory or immunosuppressive drug within 6 weeks.
10. Over-the-counter drugs, including herbal medications, and prescription drugs (other than those listed above) are not allowed for 7 days prior to first study dosing and throughout the duration of the study
11. Receipt of packed RBC's within 3 months prior to the first study dosing and throughout the study.
12. Participation in another clinical trial within 30 days prior to first drug administration.
13. Patients with an inability to communicate well with the PI and staff (i.e., language problem, poor mental development or impaired cerebral function).
14. Patients with any acute medical situation (e.g. acute infection) within 48 hours of first dosing session, which is considered of significance by the Principal Investigator.
15. Patients who will be unavailable for the duration of the trial, are likely to be noncompliant with the protocol, or who are felt to be unsuitable by the PI for any other reason.

Contacts and Locations

Contacts

Contact: Tahel Ilan Ber, MD; 972 53 803463; taheli@oberonsci.com

Sponsors and Collaborators

Tahel Ilan Ber

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Azmanov H, Ross EL, Ilan Y. Establishment of an Individualized Chronotherapy, Autonomic Nervous System, and Variability-Based Dynamic Platform for Overcoming the Loss of Response to Analgesics. Pain Physician. 2021 May;24(3):243-252.

• Responsible Party: Tahel Ilan Ber, Chief Medical Officer, Oberon Sciences LTD
• ClinicalTrials.gov Identifier: NCT03843697
• Other Study ID Numbers: OS-002
• First Posted: February 18, 2019
• Last Update Posted: February 18, 2019
• Last Verified: February 2019

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:

Intestinal Diseases; Inflammatory Bowel Diseases; Gastrointestinal Diseases; Digestive System Diseases; Gastroenteritis